Skip to main content
NIH funding notice PAR-22-037

Role of Astrocytes in Degeneration of the Neurovascular Unit in AD/ADRDs (R01 Clinical Trial Not Allowed)

Closed on February 4, 2022.

Posted
September 30, 2021
Close date
February 4, 2022
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,345,579 in first-year total cost, median $2,345,579.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1 MDCN-M (91)]1

Most frequent institutions

  1. VANDERBILT UNIVERSITY1
Competing awards under PAR-22-037 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2022STAT3 activation in astrocytes as a driver of neurovascular dysfunction in Alzheimer's disease and related dementias1RF1NS129735-01LIPPMANN, ETHANSCHRAG, MATTHEWVANDERBILT UNIVERSITY, TN$2,345,579ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.